
Atypical haemolytic uraemic syndrome (aHUS) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051103

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of the PBS subsidised for patients with
aHUS.

aHUS and listing dates

Atypical haemolytic uraemic syndrome (aHUS) is a rare and life
threatening immune condition.

Listing dates: Eculizumab - 1 December 2014.

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains restriction and item codes, contact details,
forms, the dosing schedule, repeats, weeks and days chart, links to the
PBS and Services Australia websites and codes.

Related links

Written Authority Required Drugs

Processing Authority Items - Complex Programs

Processing Written Authority Required Listings

Processing and National Demand Allocation (PaNDA)

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

                                   

-   Services Australia ABN 90 794 605 008 
